Xintela signs memorandum of understanding with CO.DON

Xintela AB (publ) announces today that the company has signed a non-binding Memorandum of Understanding with the leading European cell therapy company, CO.DON. The parties intend to collaborate on the development of Xintela’s quality markers for CO.DON’s next cell-based product and for the co- development of Xintela’s stem cell product for the treatment of osteoarthritis. […]

Xintela receives 1,5 MSEK in dispute settlement

Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation. The background to the dispute is that the counter party, who had an assignment from Xintela to validate one of the company’s patents, missed the deadline for validation with the consequence that the patent was not validated in […]

Xintela initiates a study on the treatment of cartilage damage in horses in the USA

Xintela AB (publ) announces today that the company have initiated a study, in the USA, on the treatment of cartilage damage in horses. The study is being conducted in collaboration with an eminent research group at Cornell Univesity. Xintela’s stem cells have been injected into horse joints and the study is expected to be completed […]